From Yahoo Finance: 2025-05-25 04:26:00

BMO Capital Markets raised Merus N.V. (MRUS) price target from $96 to $110, maintaining an Outperform rating after positive Phase 2 data for petosemtamab and pembrolizumab in treating HNSCC.

Data presented at ASCO showed an ORR of 63% and 79% survival rate at 12 months, with MRUS’s clinical potential receiving market support. BMO Capital’s price target increase reflects growing investor confidence.

While MRUS shows promise, some AI stocks may offer higher returns with limited downside risk. For a potentially more promising AI stock with 100x upside potential, check out our report on the cheapest AI stock.

Read more: Merus (MRUS) Price Target Raised at BMO After Positive Phase 2 Data